Utilization of hybrid LC–MS/MS for anti-drug antibody bioanalysis
As biotherapeutic technology advances, the need for adaptive, highly specific and selective bioanalytical assays are necessary to measure immunogenicity. There are several evaluations used to test the immunogenicity against developed biotherapeutics that must be monitored in vivo given the variability of reactions that may occur from patient to patient.
In this article, you will explore the current approaches for analysis of ADAs by hybrid LC-MS/MS as well as the pros and cons of hybrid LC–MS/MS for ADA analysis.
This article is part of the Bioanalysis Zone Spotlight on hybrid LC-MS/MS assays. For more expert opinions on this topic, visit our feature homepage.
In association with:
